$AVTR

Avantor® Reports Third Quarter 2026 Results

Avantor (NYSE: AVTR) reported Q3 2026 net sales of $1.7B, up 4.6% YoY, with organic growth of 5.2%. GAAP EPS was $0.30, and adjusted EPS was $0.22. The company raised FY 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow. VWR Distribution & Services saw 5.8% organic growth, while Bioscience & Medtech Products returned to organic growth at 3.6%.

Original reporting
Published Oct 28, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Avantor® Reports Third Quarter 2026 Results — source image
Decision brief

The 30-second read

$AVTRBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest stronger demand and execution, likely lifting the stock.

02

Market read

First‑day earnings release with material beat and guidance lift; relevant for traders targeting biotech and industrial supply stocks.

03

What to watch

Higher free cash flow may enable additional share buybacks or debt reduction, which could further support price.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Avantor is a global provider of mission‑critical products to life‑science and advanced‑technology customers.

Company-level read

Ticker impact

$AVTRBullishHigh confidence
Context

Avantor reported Q3 2026 results beating revenue and adjusted EPS expectations and raised FY 2026 guidance.

Expected impact

upward pressure as investors price in better-than-expected results and higher guidance

Evidence & confidence

The press release is the first disclosure of the earnings beat and guidance raise, providing fresh material for traders.

Market effects

Life‑science tools sector may see broader optimism from Avantor's beat.

U.S. markets could open higher on the earnings news.

Limited to investors tracking life‑science supply chains; no immediate global macro effect.

Counterpoint

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Avantor, Inc.

    Life‑science tools and services provider.

Related articles

$AVTRMedAI 8/10

Avantor beats Q3 estimates but shares slip on guidance

Avantor Inc. (NYSE: AVTR) reported Q3 adjusted EPS of $0.22, beating estimates by $0.01, with revenue of $1.70B, up 4.6% YoY. Shares fell 2.6% as guidance matched expectations. The company raised its full-year organic revenue growth and free cash flow outlooks. Organic revenue grew 5.2% YoY, with segments showing varied performance.

$AVTRMedAI 8/10

Avantor (NYSE:AVTR) reports upbeat Q3 2026

Avantor (AVTR) reported Q3 2026 revenue of $1.70B, beating estimates by 3.4% YoY. Adjusted EPS was $0.22, a 5.6% beat. Adjusted EBITDA was $256.9M, a 2.6% beat. Management raised full-year EPS guidance to $0.82. Operating margin improved to 8.2%, while free cash flow margin decreased to 9.2%. Organic revenue grew 5.2% YoY.

$AVTRHigh

Avantor® Reports Third Quarter 2026 Results

Avantor, Inc. (AVTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avantor® Reports Third Quarter 2026 Results • Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2% • Diluted GAAP EPS of $0.30; adjusted EPS of $0.22 • Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow guidance RADNOR, Pa. –

$AVTRHigh

A $712 million loss at Avantor gave way to $203 million in profit year over year

Avantor reported a net income of $203 million for Q3 2026, reversing a $712 million loss from the previous year. Net sales rose 4.6% to $1,698.3 million, with organic growth at 5.2%. Adjusted EPS was $0.22. The company raised its FY 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow. CEO Emmanuel Ligner attributed the results to strategic focus and improved execution.